
Dr. Chovatiya discusses the neuroinflammatory mechanisms of PN.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Brian Kim provides an overview of itch in type 2 inflammatory skin diseases and explains how the shared and unique mechanisms that drive inflammation and itch mediate each disease in distinct ways.
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson outlines why early, targeted control of type 2 inflammation may modify the course of atopic dermatitis by addressing upstream drivers of barrier dysfunction, dysbiosis, and itch.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Brian Kim explores the histaminergic and nonhistaminergic mechanisms of itch, highlighting how type 2 cytokines like IL-4 serve as central orchestrators of neuronal sensitization and immune–nervous system cross-talk.

Highlights from the ADVENT symposium at the Inflammatory Skin Disease Summit (ISDS) 2023 exploring the role of type 2 inflammation in atopic dermatitis.

Professor and Stiefel-endowed Chair of Medical Dermatology at the Dr. Phillip Frost Department of Dermatology at the Miller School of Medicine at the University of Miami; Director of the Miami Itch Center, Florida, US

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how type 2 inflammation contributes to dysbiosis, skin infections, and itch in patients with AD.
Prof. Metz discusses the unique clinical presentations of PN and CSU and explores the shared and distinct cellular underpinnings of itch and inflammation in both diseases
An infographic exploring the pathophysiology of prurigo nodularis and the role of type 2 inflammation.

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD
This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.